Releases Geral
Cellebrite Appoints Renowned Cybersecurity Expert Sigalit Shavit as Chief Information Officer
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 1 de agosto de 2024
Cellebrite DI Ltd
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the appointment of Sigalit Shavit as Chief Information Officer (CIO) who begins her role today, August 1, 2024.
Shavit joins the Companys Leadership Team, bringing with her more than 30 years of experience to Cellebrites information technology and security team. In this newly established position that reports to CEO Yossi Carmil, Shavit will play a pivotal role in scaling the Companys ability to innovate and support customers as they strive to continue accelerating justice around the globe.
Shavit joins Cellebrite at a time when the Companys technical innovation and infrastructure is paramount to supporting customers to stay ahead of the growing sophistication of criminals and the ever-increasing growth of digital evidence. She will focus on ensuring that Cellebrites information technology and security organizations continue supporting the day-to-day needs of the business, responding decisively to ever-evolving cyber threats, leveraging AI and accelerating innovation.
Sigalits expertise in information technology and security and enabling innovation for enterprise SaaS companies, elevates Cellebrites ability to advance its mission of accelerating justice, said Cellebrite CEO Yossi Carmil. We are fortunate to gain both her knowledge and leadership, which allows us to better serve our customers and employees.
Named one of the Top 25 Women Leaders in Cybersecurity in multiple publications, Shavit has held CIO and COO roles with FedEx Express, ECI Telecom, CyberArk and most recently KTrust. During her tenure with CyberArk, she played a critical role through its transformation to an enterprise-grade cloud/SaaS company.
It is a great honor to be here and lead a team that empowers and propels Cellebrite and its customers forward, Shavit said. I am passionate about my teams significant mission of harnessing a clear, modern digital strategy and solutions to make an impact on efficiency and accelerating innovation.
About Cellebrite
Cellebrites (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice and preserve privacy in communities around the world. We are a global leader in Digital Investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrites Digital Investigative platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on X at @Cellebrite.
Media
Victor Ryan Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910
Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e4793d6b-ce54-4dd5-af87-642468ab62e7
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO)
18 de fevereiro de 2025TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a con
Saiba Mais -
Releases Geral Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
4 de março de 2025UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults1LAI treatme
Saiba Mais -
Releases Geral Pesquisadores indicam suplementos para saúde do coração
23 de outubro de 2023DINO DIVULGADOR DE NOTÍCIAS São Paulo, SP–(DINO – 23 out, 2023) – A saúde cardiovascular em dia contribui para um melhor bem-estar, permitindo que as pessoas desfrutem
Saiba Mais